About: Nilotinib population pharmacokinetics and exposure-response analysis in patients with imatinib-resistant or -intolerant chronic myeloid leukemia

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Nilotinib population pharmacokinetics and exposure-response analysis in patients with imatinib-resistant or -intolerant chronic myeloid leukemia Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

article

Attributes	Values
rdf:type	Item
description	article (en) wetenschappelijk artikel (nl) article scientifique publié en 2012 (fr) наукова стаття, опублікована в жовтні 2012 (uk) im Oktober 2012 veröffentlichter wissenschaftlicher Artikel (de)
publication date	wds:Q58414318-41CB8BD0-783E-4D79-82F7-7EDEFC51853D
publication date	2012-10-05 00:00:00Z (xsd:dateTime)
exact match	wds:Q58414318-CC89D039-8085-4364-80E0-81D6D73C9BA4
exact match	https://scigraph.springernature.com/pub.10.1007/s00228-012-1385-4
cites work	wds:Q58414318-16A00223-7B95-4DCA-9D57-C840CFF31B48 wds:Q58414318-1899DEFD-72BE-4709-A3D0-4D00D8238615 wds:Q58414318-19A4D992-557D-4915-BC2F-C088623757BF wds:Q58414318-22BAE96F-F39E-42C8-9B8E-5C6A78B0B1D0 wds:Q58414318-35BB4E74-4B37-4BED-92C5-D9C521649589 wds:Q58414318-36603828-543F-493E-9E3C-291AE3952C46 wds:Q58414318-3D12F5DB-6285-4F93-A62D-803F92029995 wds:Q58414318-441F9F83-6C8F-4583-A320-F7A35534F328 wds:Q58414318-5B56B9E3-9F4E-46AC-B2DC-77D130EFCA2E wds:Q58414318-5D1F8E72-74C5-488D-A1C0-F84B64A5C475 wds:Q58414318-9259B47C-8B92-42B4-80A8-01F7941DDA72 wds:Q58414318-A5D56731-512A-486D-A4BF-29BF2994B1D1 wds:Q58414318-A679F1A5-319D-4040-8F68-375DD5C134B1 wds:Q58414318-ABDD26EC-4AC2-46EE-AAB9-A62F21311F5C wds:Q58414318-BB6811CF-306B-420F-B555-831B156640B3 wds:Q58414318-F09BE3BC-9614-4807-8114-52FB3F39FF02 wds:Q58414318-F9588AA9-0D0B-4CE6-9451-4D76C5562A08 wds:Q58414318-FB6DDB43-FA3D-44BE-83FD-02E3B315B1CE
cites work	Extended kinase profile and properties of the protein kinase inhibitor nilotinib Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results In vitro inhibition of UDP glucuronosyltransferases by atazanavir and other HIV protease inhibitors and the relationship of this property to in vivo bilirubin glucuronidation Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL Mechanism of indinavir-induced hyperbilirubinemia UGT1A1 polymorphism and hyperbilirubinemia in a patient who received sorafenib Prognostic discrimination in "good-risk" chronic granulocytic leukemia. Clinical pharmacokinetics of the BCR-ABL tyrosine kinase inhibitor nilotinib Imatinib mesylate for Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon-alpha: follow-up results. The small-molecule tyrosine kinase inhibitor nilotinib is a potent noncompetitive inhibitor of the SN-38 glucuronidation by human UGT1A1 A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group. Nilotinib for the treatment of Philadelphia-chromosome-positive chronic myeloid leukemia Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase Effect of grapefruit juice on the pharmacokinetics of nilotinib in healthy participants Nilotinib in patients with Ph+ chronic myeloid leukemia in accelerated phase following imatinib resistance or intolerance: 24-month follow-up results Pazopanib-induced hyperbilirubinemia is associated with Gilbert's syndrome UGT1A1 polymorphism UGT1A1 promoter polymorphism increases risk of nilotinib-induced hyperbilirubinemia Population pharmacokinetic and exposure-response analysis of nilotinib in patients with newly diagnosed Ph+ chronic myeloid leukemia in chronic phase
author name string	wds:Q58414318-27C1666E-B4B6-413F-AEC8-EDE6BE0CA43A wds:Q58414318-4A513413-D51C-49BD-A78F-9A3676361245 wds:Q58414318-4A92C989-E54E-46F0-A6EE-87C83E127EF5 wds:Q58414318-91D497C8-52E7-4719-A9FE-DFBE93949049 wds:Q58414318-DEF69D90-60EE-4B87-AD9D-85032F99489B wds:Q58414318-F7EDE227-EC19-4E8C-A84D-15B2BAE62C23
author name string	Francis J. Giles Oliver G. Ottmann Ophelia Q. P. Yin Philipp D. le Coutre Richard C. Woodman William M. Sallas
rdfs:label	Nilotinib population pharmacokinetics and exposure-response analysis in patients with imatinib-resistant or -intolerant chronic myeloid leukemia (en) Nilotinib population pharmacokinetics and exposure-response analysis in patients with imatinib-resistant or -intolerant chronic myeloid leukemia (nl)
skos:prefLabel	Nilotinib population pharmacokinetics and exposure-response analysis in patients with imatinib-resistant or -intolerant chronic myeloid leukemia (en) Nilotinib population pharmacokinetics and exposure-response analysis in patients with imatinib-resistant or -intolerant chronic myeloid leukemia (nl)
name	Nilotinib population pharmacokinetics and exposure-response analysis in patients with imatinib-resistant or -intolerant chronic myeloid leukemia (en) Nilotinib population pharmacokinetics and exposure-response analysis in patients with imatinib-resistant or -intolerant chronic myeloid leukemia (nl)
author	wds:Q58414318-16B69503-0127-48B2-BFFE-B85E86F05512 wds:Q58414318-E4768EFD-F0ED-421B-A4C3-7538636EC5B6
author	Michele Baccarani Hagop Kantarjian
title	wds:Q58414318-ECB44FF7-DDF1-4CC5-94F2-CC0DC953DBD2
title	Nilotinib population pharmacokinetics and exposure-response analysis in patients with imatinib-resistant or -intolerant chronic myeloid leukemia (en)
page(s)	wds:Q58414318-665EC5FF-CBE1-4688-A247-E3D00202F473
page(s)	813-823
instance of	wds:Q58414318-69785959-D8D6-47C7-8EED-2BDD962204D4
instance of	scholarly article
main subject	wds:Q58414318-24C30690-FDCF-4189-8DCE-4824E275C2C8 wds:Q58414318-BE0EDFEC-A4F8-434B-AB71-82C4B6D2B237 wds:Q58414318-F2B07AC6-0755-4C7C-8D01-13873FAB019F wds:Q58414318-F6252C91-871F-438D-B8B2-5C0D2964DD57
main subject	leukemia chronic myeloid leukemia pharmacokinetics myeloid leukemia
PubMed ID	wds:Q58414318-FA2E7B40-99F2-4B43-AF24-B262A9ABB9B8
PubMed ID	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/23052406
PubMed ID	23052406
published in	wds:Q58414318-15E216B3-D52F-4400-B7C5-28779D84837E
published in	European Journal of Clinical Pharmacology
issue	wds:Q58414318-9E3A36E6-B7A3-4210-93A3-3F04DFE2516B
volume	wds:Q58414318-DA6D6621-4133-4E98-94ED-7EBB034D0785
issue	4
volume	69
DOI	wds:Q58414318-B2F6467B-321A-4690-88E2-5CBD683BCCBC
DOI	http://dx.doi.org/10.1007/S00228-012-1385-4
DOI	10.1007/S00228-012-1385-4
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q58414318
is cites work of	Exposure-response relationship of ramucirumab in patients with advanced second-line colorectal cancer: exploratory analysis of the RAISE trial Multicenter phase II clinical trial of nilotinib for patients with imatinib-resistant or -intolerant chronic myeloid leukemia from the East Japan CML study group evaluation of molecular response and the efficacy and safety of nilotinib Practical guidelines for therapeutic drug monitoring of anticancer tyrosine kinase inhibitors: focus on the pharmacokinetic targets Pharmacokinetics and pharmacodynamics of dasatinib in the chronic phase of newly diagnosed chronic myeloid leukemia. Germline oncopharmacogenetics, a promising field in cancer therapy

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 190 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software